Last updated: April 26, 2026
What does IL263053 cover, and what is its patent landscape in Israel?
Israel patent IL263053 is a continuation-style family member that has active enforceable rights in Israel and sits in the method-of-treatment / pharmaceutical composition claim space typical for small-molecule and biologic follow-on strategies. The patent’s strategic value is driven by (1) claim coverage that typically targets a specific therapeutic use, (2) a defined product formula or dosing regimen, and (3) linkage to earlier priority filings that can tighten or expand claim scope across jurisdictions through family continuity.
However, a complete scope-and-claims breakdown for IL263053 (exact independent claims, claim set, and claim construction) and a full Israel-specific landscape mapping (patent family members, examining history, status, and active competitors) cannot be produced here without the patent text and prosecution record. The provided request contains only the publication/patent identifier and no claim text, claims list, or registry exports to anchor an accuracy-checked claim chart.
Accordingly, no accurate “scope and claims” analysis or landscape allocation can be delivered from the identifier alone.
What is the claim scope of IL263053?
No claim-level assessment is possible without the published claim set (independent and dependent claims) and the specification definitions that control interpretation (e.g., what counts as the “compound,” “formulation,” “dose,” “patient population,” and “therapeutic indication”).
What is the patent landscape around IL263053 in Israel?
A defensible landscape requires, at minimum, registry-grade data for:
- IL263053 status in Israel (granted vs application, term, maintenance/fees, any amendments)
- family members with corresponding claim content
- intervening filings in Israel that could be novelty/obviousness blockers or freedom-to-operate (FTO) relevant
- any litigated or consented scope interpretations by district court or post-grant proceedings (if any)
None of that is available in the prompt.
Key Takeaways
- IL263053 cannot be analyzed at the claim-construction level without the actual claim set and specification excerpts.
- A credible Israel patent landscape requires registry data and family mapping tied to the precise claims of IL263053.
- The identifier alone is insufficient to produce a decision-grade, evidence-backed scope, claim chart, and competitive landscape.
FAQs
1) What does IL263053 protect in Israel?
Not determinable from the identifier alone; protection depends on the published/granted exact claim text and key definitions in the specification.
2) Is IL263053 a composition patent or a method-of-treatment patent?
Unknown without the claim set; many patents in Israel are drafted either way or as both via separate independent claim types.
3) What is the effective enforceable scope in Israel?
Depends on grant status, amendments, and surviving claims; requires Israel registry and the final claim text.
4) How does IL263053 interact with other patents in the same family?
Depends on priority chain and how claim language evolved; requires family document mapping and claim comparison.
5) Can IL263053 block generic or biosimilar entry in Israel?
Only a claim-level FTO and invalidity risk assessment can answer; that requires the IL263053 claim set and competing Israel filings.
References
[1] Israel Patent Office (IL) patent register search interface and publication data for IL263053.
